In this review, we will discuss the biology and development of CD8 + Tregs, their contribution to the tolerance status apart from CD4 + Tregs, their manufacturing for clinical use, considering open questions/uncertainties and future technically accessible betterments notably through genetic modifications.
| MAIN CHAR AC TERIS TI C S OF CD8 + REG UL ATORY T CELL S
Despite a streamline work from several groups, the definition of CD8 + Tregs remains the major problem of this cell subset population and the reason for them not being assessed in clinical protocols. This lack in assessment is making marker discovery even more problematic and slow, leading to a vicious circle. The fact that, at steady state, expression of FOXP3, a sensitive marker of Treg, is lower in the CD8 + T cell population compared to the CD4 + T cell population in mouse, rat and human, 3 has contributed to this disregard of CD8 + Treg's potential and interest, despite in vitro and in vivo data demonstrating their suppressive capacity. In addition, the methylation status of FOXP3 in human CD8 + Tregs showed an intermediate level of demethylation compared to one of the CD4 + Tregs for some locus of the FOXP3 gene. 3 We showed that following ex vivo stimulation, human CD8 + Tregs sorted based on the expression of CD45RC, a splicing variant of the CD45 molecule key in the signaling of T cells that we use as a marker to isolate CD8 + Tregs [4] [5] [6] ; FOXP3 is expressed by all expanded CD8 + Tregs that display highly upregulated levels of expression vs. blood unstimulated CD8 + FOXP3 + , suggesting that FOXP3 can correlate with the in vivo and in vitro suppressive potential of human CD8 + Tregs. 3 In contrast, in a rat model of transplantation tolerance following costimulation blockade inducing in vivo CD8 + Tregs, FOXP3 was not upregulated, 4 nor was it in a model of tolerance in rat using donor antigen therapy. 7 FOXP3 is also not found particularly expressed in mouse CD8 + Tregs, and rather the transcription factor HELIOS or the surface marker CD122 + or CD28are used to identify CD8 + Tregs in mice. 8, 9 Other surface markers were also suggested and among the most frequently used CD25, CD127, GITR, CD39, Lag3, and CTLA-4 that are used in different contexts and different species to identify CD8 + Tregs and analyze their suppressive activity in vitro and in vivo in autoimmune diseases, immune reactions to non-self, cancer and materno-fetal tolerance. 2, 10 Indeed, using a combination of these markers to identify CD8 + Tregs, their suppressive action has been demonstrated in autoimmune diseases such as in the experimental autoimmune encephalomyelitis model, [11] [12] [13] multiple sclerosis, [14] [15] [16] systemic lupus erythematosus (SLE) 17, 18 and primary biliary cirrhosis, 19 in infection in humans with mycobacteria, human immunodeficiency virus or epstein-barr virus, [20] [21] [22] [23] in cancer in humans and mice [24] [25] [26] or in transplantation in humans, mice and rats. 3, 4, [27] [28] [29] [30] [31] [32] was used to identify antibody-suppressor FOXP3 − CD8 + cells in mice and essential in their function of suppression of humoral immunity, reducing germinal center B cells and CD4 + T follicular helper cells in the context of hepatocyte transplantation. 33 A very recent study of single cell RNA sequencing on CD4 + Tregs has highlighted the importance of some transcription factors and extra-membrane molecules. 34 This work showed that CD4 + Tregs and CD4 + Tconvs can be distinguished by the ubiquitous expression of FOXP3, IKZF2 (IKAROS), TNFR2, IL2RA and IL2RB in mice and humans. Analysis using DGE-RNA sequencing of fresh and activated CD8 + CD45RC low/-Tregs allowed us to show the increase in FOXP3 expression and suppressive molecules after activation. However, nowadays no single cell RNA sequencing study is being published on CD8 + Tregs. Our analysis of single cell RNA sequencing data on fresh CD8 + CD45RC low/cells from healthy volunteers confirms the expression of molecules known in CD4 + Tregs such as TNFR2 but never clearly showed before in CD8 + Tregs (unpublished data).
Soluble factors can also be used to identify and even sort CD8 + Tregs since the development of kit using bispecific antibodies allows the sorting of live cytokine-secreting cells. We have shown that sorted human IFNγ + IL-10 + CD8 + CD45RC low/-Tregs were more potent suppressor cells than the rest of the CD8 + CD45RC low/-Tregs 3 and this was also indicative of the role of these cytokines in CD8 + Treg suppressive activity, in particular IFNγ (Figure 1 ). Our interest in IFNγ came from the observations that blocking its activity abrogated the CD8 + CD45RC low/-Treg suppressive activity in a model of allogeneic cardiac transplantation. 4 We further demonstrated that indeed, IFNγ induced indoleamine 2,3-dioxygenase (IDO) production by endothelial cells (ECs) of the graft and plasmacytoid dendritic cells, an enzyme catabolizing tryptophan essential for effector T cells proliferation. 4, 35 IFNγ was also involved in fibroleukin-2 (FGL2) induction, a cytokine acting further through regulatory B cell induction. 36 We have also shown that IL-34, a recently discovered cytokine involved in monocyte/macrophage differentiation, was secreted by approximately half of FOXP3 + CD8 + and CD4 + Tregs. 37 We showed that IL-34 was involved in FOXP3 + Treg suppressive activity and acted as a suppressive cytokine since administration in a model of allogeneic cardiac transplantation in combination with a suboptimal dose of rapamycin-induced transplant tolerance. This was the first description of a role for this cytokine in T cell biology and transplantation. 38 Thus, a complex regulatory network of cells around CD8 + Tregs is acting to sustain tolerance. 39 Other more classical cytokines such as TGFβ have also been described as playing a role in CD8 + Treg suppressive activity. 2 Some of these molecules or mechanisms of action have been evidenced by study of the fetal-maternal interface. 40, 41 Indeed, in maternal tolerance where the allogeneic fetal trophoblast invades maternal tissues and interacts with maternal leukocytes, the immune system needs to be regulated to tolerate the presence of the fetus. CD8 + T cells are the main component of decidual T cells and CD8 + Tregs have been evidenced as important in the maintenance of a normal pregnancy. [42] [43] [44] Decreased number and altered function of Tim-3 + CTLA-4 + CD8 + T cells correlated with miscarriage and blockade of Tim-3 and CTLA-4 inhibited production of anti-inflammatory cytokines and were detrimental in the maintenance of the pregnancy. 42 Allogeneic fetal trophoblasts express the non-classical major histocompatibility complex (MHC) class I molecule human leukocyte antigen G which is needed for immune tolerance establishment and was shown to increase the number of Tregs. 45, 46 MHC restriction preference of CD8 + Tregs has been shown as important for their suppressive activity and for some subpopulations of CD8 + Tregs different from what has been described for CD8 + Teff cells. Particularly in mice and humans, the best described population of mouse CD8αα + TCRαβ + Tregs or human CD8 + Tregs (no specific phenotype associated except pMHC restriction) has been described to preferentially recognize non-classical MHC class I molecules Qa-1 or HLA-E that are orthologous genes. [47] [48] [49] [50] These non-classical MHC class I restricted populations have the property to recognize TCR, MHC or heat shock protein derived peptides (ie Qdm, HSP60sp) presented by Qa-1 or HLA-E. 50, 51 We have also shown that this capacity to recognize MHC-derived peptide is not restricted to non-classical MHC class I molecule but also true for classical MHC class I molecule. We showed that peptides derived from a polymorphic region of the β1domain of MHC class II molecules from the donor and presented by recipient classical MHC I molecules can expand CD8 + CD45RC low/-Tregs and induce tolerance in transplantation in an antigen-specific manner in rats 7, 52 and humans (unpublished data).
In this context, the identification of new membrane markers for CD8 + Treg populations to better define a consensus phenotype is a major challenge and objective for the future. In addition, a better understanding of the mechanisms involved in their development and function would allow to better understand and optimize their clinical potential. 
| S IMIL ARITIE S , DIFFEREN CE S AND SYNERG IE S B E T WEEN CD8 + AND CD 4 + TREG S
A major aspect that remains to be properly addressed given the lack of assessment of CD8 + Tregs in diseases is the similarities, differences and synergies that could exist between CD8 + and CD4 + Tregs that could emphasize the interest in CD8 + Tregs (Table 1 ). whereas donor-specific blood transfusion as well as anti-CD45RC
| Function and mechanisms of action
MAb or IL-34 administration tolerance was dependent on both CD8 + and CD4 + Tregs. 37, 55 In these two last models adoptive transfer of each of the CD8 + or CD4 + Treg subsets resulted in tolerance in a fraction of the recipients that was lower than the one obtained when all Tregs were transferred. 37, 55 Similarly, in a mouse model, GVHD was most efficiently inhibited when both CD4 + and CD8 + Tregs were used associated and the presence of CD8 + Tregs preserved a Teffmediated graft versus leukemia effect that was lost when CD4 + Treg cells were used alone. 56 Interestingly in the perspective of simultaneously using CD8 + and CD4 + Tregs, both Treg subsets could be produced in vitro at the same time, such as when they are induced in the presence of APCs treated with IL-34. 37 Finally, the suppressive capacity of CD8 + and CD4 + Tregs to suppress naive and memory CD4 + T effector response has been compared in the transplantation field by different groups. This is a very clinically relevant situation to analyze the role of naive vs. memory CD4 + T effector responses, since both are activated at different time points during transplantation and memory T cell response is described as particularly difficult to control with usual immunotherapeutic or even immunosuppression protocols. Both naive and memory CD4 + Treg cells only suppressed naive and not memory CD4 + and CD8 + T responses. 57 In contrast, CD8 + Treg cells suppressed both naive and memory effector CD4 + T cell responses. 58 As far as mechanisms of action are concerned, several cytokines have been described as playing a role for both CD8 + and CD4 + Tregs, although not necessarily in all models or in vivo or in vitro situations. As an example, IL-10-mediated suppression has been described for CD8 + CD122 + Tregs in mice 54 IL-34 is a cytokine with immunoregulatory properties by at least inducing M2 macrophages 38 and that is expressed by both CD8 + and CD4 + Tregs and is able to prolong heart allograft survival. 37 FGL2 immunoregulatory properties were first described in CD4 +
Treg cells, 62 FGL2 expression was then reported in mouse CD8αα
Treg cells 63 and in rat CD40Ig-induced CD8 + CD45RC low/-Treg cells functions. FGL2 function is at least mediated through the FcγRIIB receptor inhibiting dendritic cell maturation, inducing B cell apoptosis 64 and generating regulatory B cells through unknown mechanisms. 36 IFNγ is a mechanism of suppression not only of CD8 + Tregs 3,65-67 but also of CD4 + Tregs. [68] [69] [70] The mechanism of suppression by IFNγ includes actions on endothelial and antigen presenting cells, such as induction of IDO and FGL2.
IL-35 has been previously described as expressed by CD4 + Tregs 71 but it has also been described as expressed and playing a suppressive role for tumor-associated CD8 + Tregs. 66, 72 Although IFNγ has proinflammatory consequences it has also been described as having pro-tolerogenic actions, through the production of molecules such as IDO, iNOs and FGL2. 68 IFNγ has been described as produced by several CD8 + Treg types 3, 4, 65, [73] [74] [75] [76] [77] although the function of IFNγ in CD8 + FOXP3 + cells has not been specifically analyzed. In contrast, and although suppression through IFNγ has been described by CD4 + Tregs in certain models 70, 78 CD4 + FOXP3 + Tregs in general produce low levels of IFNγ.
PD-1 has been described in mice to be expressed at lower levels in CD8 + Tregs vs CD4 + Tregs 32 but PD-1 expression is important for CD8 + Treg function, 79, 80 as it is for CD4 + Tregs. 81, 82 Additionally, PD- Although cytotoxicity could be expected to be a widespread mechanism of suppression by CD8 + Treg cells and not of CD4 + Treg cells, only in some cases CD8 + Tregs have been described as cytotoxic 85-88 and CD4 + Tregs have also been shown in some instances as cytotoxic, [89] [90] [91] [92] [93] [94] thus this mechanism is shared by both types of Tregs.
| Metabolic activity
Mechanistic target of rapamycin (mTOR) through mTOR complex 1 (mTORC1) and mTORC2 regulates activation and proliferation through the phosphorylation of several transcription factors. 95 Mechanistic target of rapamycin signaling is high and increases the inflammatory response in Teff cells maintaining glycolysis whereas mTOR activity is low in CD4 + Tregs. 96 Inhibitors of mTOR such as rapamycin directly bind and inhibit mTORC1. Activity of mTORC1
is necessary for CD4 + Treg cell function to maintain their metabolic status through lipogenesis. 97 in vitro while they do in vivo. 111, 112 In contrast, IL-15 is necessary for optimal CD8 + Tregs expansion in vivo 113, 114 and in vitro. 3, 54, 61 In vitro expansion of CD8 + Tregs in the same conditions used to expand CD4 + Tregs has shown lower suppression activity in some cases but this may be related to the use of culture conditions that are optimal for CD4 + and not CD8 + Tregs. 115 In this regard, we have observed that the use of beads coated with anti-CD3 and anti-CD28
| Proliferation in vitro and in vivo
MAbs ideal for the culture of CD4 + Tregs is toxic for human CD8 + Tregs while being well-tolerated by mouse CD8 + Tregs (manuscript in preparation). It is then important when comparing in vitro cultured CD8 + and CD4 + Tregs to use the best culture conditions for each cell type.
| B I OLOGY AND DE VELOPMENT OF CD8 + TREG S

| Origin
The thymic origin of CD8 + nTregs is however still poorly described.
In 2016, the presence of CD8 + CD28 low Treg cells in peripheral blood mononuclear cells (PBMCs) and in children's thymuses was described and also their thymic origin demonstrated. 9, 116 CD8 + Tregs are associated with different phenotypes depending on the studies (CD122, CD28, CD45RC, CD103, PD-1) but mostly their phenotype is rather associated to a differentiation status of central memory cells or effectors memory as characterized by the absence of CD28, CD62L or CD122 expression. 3, 117 Other teams describe them rather through the expression of CD44, CCR7 and CD62L which are markers of central memory cells 3, 73 or CD122 + and CD28 + . 32 shown to efficiently induce and mediate their tolerogenic effect through CD8 + Tregs. Blockade of the CD40/CD40L costimulatory pathway is a well-known strategy in transplantation for its potential in animal models in tolerance induction, although its translation to the clinic has been slowed down due to thromboembolic events. 126 We have shown that blockade of the CD40/CD40L pathway using an adenovirus encoding CD40Ig, a chimeric molecule, in a model of fully incompatible cardiac allotransplantation in rats resulted in tolerance induction dependent on CD8 + CD45RC low/− Tregs. 2, 4, 35, 127 Blockade of the 4-1BB/4-1BBL costimulatory pathway together with immunization in mice was also shown to induce antigen-specific CD8 + Tregs acting in a IFNγ and TGFβ dependent manner. 59 In this model IFNγ directly stimulates CD8 + Tregs to induce a TGFβ-based suppression. 59 In contradiction, 4-1BB has been shown as important for the suppressive activity of CD8 + Tregs in a model of allergic inflammation. 128 We and others showed that IFNγ and TGFβ were key mediators of the suppressive activity of CD8 + Tregs. 4, 68, 129, 130 Blockade of ICOS/B7h costimulation also showed potent induction of alloantigen-specific CD8 + PD1 + Tregs in vivo in a model of heart grafts in mice. 131 More surprisingly, targeting CD3, a molecule expressed by definition by Treg, has shown effectiveness in inducing both CD4 + and CD8 + Tregs in a collagen induced arthritis model of rheumatoid arthritis in mice. 132, 133 In this model, CD8 + Tregs, unlike CD4 + Tregs, potently inhibited Th17 responses, thereby inhibiting a wider range of inflammatory pathways. The authors also showed that monocyte membrane bound TNFα increased FOXP3 expression in CD8 + T cells. Administration of hOKT3g1 (Ala-Ala) in patients with type 1 diabetes mallitus halted disease progression for >1 year and was associated with increased CD8 + FOXP3 + Tregs. 134 Induction of CD8 + Tregs was dependent on TNF and associated with TNFR2 expression by the CD8 + Tregs. 135 There is a ying and yang action observed by several groups for cytokines such as TNFα and IFNγ. Anti-TNF antibodies are used in Crohn's disease and have shown effectiveness in management of the disease but also common failure. 136 The importance of action of these cytokines on and by CD8 + Tregs, but also more recently by CD4 + Tregs, 137 should certainly be taken into consideration in the potential limited effect of cytokine-targeting drugs in autoimmune diseases.
Co-administration of CD8 + Treg therapy with costimulation blockade is also showing synergistic efficacy. In a model of skin transplantation in mice, CD8 + CD122 + PD-1 + Tregs expanded ex vivo combined with costimulation blockade of CD40/CD154, but not of B7/CD28, synergizing to prolong the allograft survival in an IL-10-dependent manner. 113 In fact, blockade of the B7/CD28 costimulation pathway has been also shown by us as being detrimental to CD8 + Treg-mediated tolerance. Simultaneous blockade of the CD40/CD40L and CD28/B7 interactions using CD40Ig and anti-CD28 mAbs abrogated in 50% of the recipients tolerance, inhibited CD8 + Treg induction and modified the regulatory mechanisms taking place in the remaining recipients that did not reject their allograft, 138 suggesting that the B7/CD28 costimulation is required for CD8 + Treg expansion and function. Cytokine therapies such as the one using IL-34 has been shown to also modulate the Treg/Teff balance by differentiating monocytes into regulatory macrophages that could in turn induce CD8 + and CD4 + Tregs responsible for the long-term tolerogenic effect. 37 The type and dose of immunosuppressive drug treatments are critical to ensure patient safety whether the cell therapy is not effective, but should not be deleterious to the adoptively transferred CD8 + Treg cells. We have recently shown that mycophenolic acid stopped their proliferation in contrast to rapamycin. 3 In addition, we observed that rapamycin promoted CD8 + Treg proliferation and suppression capacities. 3 145 This rational strategy will be applied to the Eight-Treg clinical trial.
| CD8 + TREG CLINI C AL TRIAL IN K IDNE Y TR AN S PL ANTED PATIENTS
It is important to note that the Treg cells product, with or without genetic modifications, is classified as an Advanced Therapy activity of both CD4 + and CD8 + Treg subsets, 84 while the CTLA-4 and LAG3 markers of human CD8 + Tregs may have a role. 27, 28, 156, 157 It is important to note that the CD8 + Tregs used for the Eight-Treg trial show no phenotypic sign of exhaustion after 2 weeks of culture, and survive and still proliferate for at least 1 month in vitro. 3 Co-treatment with IL-2 is considered to promote the persistence of CD8 + Tregs in patients, as required for ex vivo culture. 3, [103] [104] [105] [106] [107] Encouraging results were obtained in HSCT patients treated with low dose IL-2, expanding a functional CD4 + Foxp3 + Treg subset associated with a lower incidence of GVHD while maintaining a low viral infection incidence 158, 159 (NCT00539695). However, soluble circulating IL2-R can mediate sequestration of IL-2 and limit its effect 160 (NCT01927120). Further investigations regarding the dose and duration of IL-2 administration are required. Here again, rapamycin can promote the persistence and stability of CD8 + Tregs face to an inflammatory environment. 3, 161 To cope with the lack of persistence of the infused Tregs, we could multiply the injections of CD8 + Tregs as in CD4 + Treg-based clinical trials (RSMU-001: NCT01446484, Treg: NCT01624077, NCT02749084). This process requires the production of a large amount of Tregs and reliable storage with a stable suppressive function. 162 Long-term culture and stable cryopreservation of CD8 + Tregs are possible. 3
| NE W SOURCE S OF TREG S: D IFFERENTIATI ON FROM PLURIP OTENT S TEM CELL S
Although cell therapy with Tregs is very promising for treating GVHD, rejection after transplantation and autoimmune diseases, one of the limitations is the source of cells to be injected. The cell source must be easily accessible and allow a large number of cells to be donated. PBMCs and cord blood cells are the most traditional sources. They also allow autologous treatments. However, the prevalence of Tregs in these sources is quite low and requires more rounds cell expansion. 163 Recently a study has shown the possibility of using Tregs from the thymus of children recovered after cardiac surgery. Indeed, cardiac intervention in children routinely requires the removal of the thymus and these thymuses are then thrown away. However, there are more Tregs cells in a child's thymus than in an adult's entire blood volume and 100 times more than in a unit of cord blood, making it a very interesting source. 164 Nevertheless, this source requires a very complex organization between surgical teams and teams of biologists to collect the thymus and extract the cells and the Treg product would be from allogeneic sources to the recipient.
Since 1998, human embryonic stem cell has been the ultimate source of cells for regenerative medicine. Thanks to their pluripotent characteristic, they can differentiate into any cell in the body and are able to renew themselves indefinitely. More recently, induced pluripotent stem cells (IPSC) were obtained by reprogramming of adult somatic cells using transduction of four factors essential for pluripotency in mice and then in humans. 165, 166 This IPSC could lead to tailor-made regenerative medicine. This avoids alloreactivity and therefore potentially reduces the doses of immunosuppressive treatment, which has many side effects. In tiation of these T-IPS the antigenic specificity is preserved. [168] [169] [170] [171] All these studies showed the great potential of IPS-derived T cells as an alternative source for T cell-based immunotherapy in cancer treatments. This is why the use of ES-or IPSC-derived Tregs is also considered with great interest in the treatment of GVHD or in au- 
| ENG INEERING OF CD8 + TREG S
| TCR/CAR and others
In recent years, many clinical trials have used polyclonal Tregs or expanded Tregs. 176 However, polyclonal Tregs are non-specific and can potentially cause global immunosuppression. Several studies have demonstrated that the use of antigen-specific Tregs was much more effective than polyclonal Tregs in animal models. 7, 52, 177, 178 Specific antigen Tregs can be generated by cultivating them with APCs containing specific antigens or using TCR engineering techniques. However, expansion with APCs can remain quite ineffective because of the few specific antigen Tregs present in the original polyclonal cells and difficulty to translate to the clinic.
Therefore, TCR engineering appears as a promising technique to obtain antigen-specific Tregs. [179] [180] [181] Nevertheless, the use of TCRs remains restricted to a given MHC and TCR cannot be identified in all diseases, this is why another strategy providing antigen specificity emerged a few years ago with spectacular results in cancer:
the CAR. The extracellular part of this synthetic receptor binds to surface molecules on the cells independently of the MHC, unlike TCRs, and independently of the patient's HLA haplotype since the specificity is provided by antibody sequences. 182 The manufacture of CARs has evolved over the years, today there are four generations of CARs. The 1st generation contains a single chain variable fragment of an extracellular monoclonal antibody, a transmembrane domain and finally an intracellular domain CD3z to conduct the signal. 183 For the second generation, a costimulation domain linked to CD3z has been added: CD28 (cytotoxic potential) or 4-1BB (persistence and decrease exhaustion). 184 The third generation contains the CD3z, CD28 and 4-1BB domains which improve persistence and anti-tumor activity. 185 Finally, the fourth generation called T cell redirected for universal cytokine-mediated killing (TRUCKs) for TRUCKs allows the production of inducible cytokines after the recognition of the molecule of interest by the CAR. This system could make it possible to recruit non-CAR cells on the tumor site, for example through the secretion of chemokines to promote their elimination. 186 Cells are now mainly used for cancer immunotherapy. CAR-T cells targeting CD19 are effective in the treatment of malignant hematological diseases in preclinical and clinical trials. 182, 187, 188 They were approved by the US food and drug administration for clinical treatments in 2017. This technology has shown its full potential in cancer therapy, it is now extended to therapies using Tregs. CAR Tregs' ability to control an inflamatory bowel disease in mice 189 and in another model of colitis in mice 190 has been demonstrated. Clinical studies show the use of Tregs to prevent GVHD after allogeneic hematopoietic stem cell transplantation. [191] [192] [193] However, one study shows that the transfer of Tregs after hematopoietic stem cell transplantation can lead to overall immunosuppression and thus an increase in viral infections in the patient. 194 This is why a more specific therapy is being sought and the use of antigen-specific CAR Tregs is on the rise. HLA-A2 has been shown to be a common antigen of incompatibility in transplantation with a prevalence of approximately 50% in European phenotype patients. Over the last 3 years, three groups have used anti-HLA-A2 antibody sequences to generate CARs and shown that anti-HLA-A2 CAR-transduced CD4 + Tregs in xeno-GVHD and skin grafts in NSG mice humanized with PBMCs had a higher suppressive potential than control CD4 + Tregs. 178, [195] [196] [197] This year, our group has shown for the first time the proof of concept that CD8 + CD45RC low/-Tregs expressing a CAR directed against HLA-A2 are significantly more suppressive on CD4 + and CD8 + effector T cell in vitro than polyclonal Tregs and are able to inhibit graft rejection and GVHD more effectively than polyclonal Tregs in vivo in a model of HLA-A2 + skin graft rejection and HLA-A2 + PBMC GVHD in NSG mice (manuscript submitted). The transfer of antigen-specific Tregs offers a promising strategy against pathologies characterized by aberrant immune activation such as transplant rejection and autoimmune diseases. In addition, the antigenic specificity provided by the CAR allows a much more targeted therapy and thus avoids the side effects of an overall immunosuppression of the patient.
In addition, insertion of a CNI resistance gene into Tregs is an interesting option considered for future clinical trials (the TacRes trial). Indeed, the stability of CD8 + Treg function may be optimized by genetic modifications. The CRISPR/Cas9 system opens new possibilities for stabilizing Foxp3 expression in Tregs. 198 Besides, demethylation of Foxp1 could help Foxp3 DNA binding and increase CD8 + Treg suppressive function as reported for CD4 + Tregs. 199 Otherwise, targeting genes such as HIF-1alpha KO would switch Treg metabolism from glycolytic-driven migration to an oxidative phosphorylation-driven immunosuppression. 200 On the other hand, overexpression of Hdr1 could help Tregs to face to ER stress response to an inflammatory environment. 201 Further studies are required to assess the relevance of targeting these genes to improve the stability of CD8 + Tregs.
| Safety system
To avoid any adverse event, genetic modifications to introduce a safety switch into the cells prior to the adoptive transfer have been developed. There are several techniques involving suicide genes. The two most commonly used techniques are Herpes Simplex virus thymidine kinase (HSV-TK) and human inducible caspase 9 (iCasp9). HSV-TK is the first suicide gene studied. The interaction of HSV-TK with Ganciclovir leads to cell suicide by polymerase and DNA synthesis disruption. 202 This technique has been tested in clinical phases I and II in France. 203 While effective, this approach is limited by the immunogenicity of HSV-TK expression with resultant rejection of modified cells. 204 iCasp9 is very effective, 30 minutes after the injection of the molecule allowing his dimerization (CID) there is elimination of 90% of the T cells modified for iCasp9. The dimerization of iCasp9 with CID results in a cascade of caspases that is responsible for cell death by apoptosis. [204] [205] [206] [207] However, this approach also has disadvantages such as the possible toxicity of the remaining cells and the possible autonomous dimerization of iCasp9 leading to the elimination of the cells before their action. An iCasp9 gene has been introduced into the CAR construct for effector T cell-based therapy clinical trials in cancer (NCT03696784, NCT03016377, NCT03721068, NCT01822652). 208 Other approaches such as controlling the intensity or toxicity of T or Treg cells by adding an "on switch" system via the CAR are being studied. The T cell response can be controlled by the recognition of two antigens simultaneously. [209] [210] [211] Kloss et al showed in a mouse prostate cancer model that T cells co-transduced with a CAR against two antigenic prostate tumors (prostate-specific membrane antigen and prostate stem cell antigen) were able to destroy tumors expressing both antigens. However, these cells have no effect on cells with only one of the two antigens. 210 Conversely, it is possible to transduce T cells with an inhibitory CTLA-4-or PD-1-based iCAR to limit cytokine secretion, cytotoxicity, and proliferation. 212 Overall, all this work provides an opportunity to specify selectivity and mimic the activity of modified T cells in order to reconcile processing power and safety.
| CON CLUS ION
Altogether, we believe that CD8 + Tregs are powerful players in immune tolerance that should be developed further through careful and systematic analyses in rodent models and human diseases.
Although there is always some way to go, all these recent advances and upheavals will bring us to a better understanding of the CD8 + Tregs and the next generation CD8 + Tregs usable for cell therapy in transplantation and autoimmune diseases.
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